Aucta is developing a range of new therapeutics that fulfill unmet needs and provide tangible patient benefits. With an early and ongoing emphasis on CNS disorders, in particular, Epilepsy, Parkinson’s disease, we are also focusing on new Ophthalmics, and Inhalation therapies. To support this, the company has 3 distinct proprietary technology platforms: Auc-Ped (liquids), Auc-Trol (controlled release oral solids), and Auc-Del (specialized dosage forms).
We continuously evaluate and evolve our technology toolbox. We plan to initiate new areas of research based on new proprietary technologies that have platform characteristics and can produce innovative products.